With the skyrocketing popularity of GLP-1 RAs, some lesser-known side effects, including anemia, are coming to light.

Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in ...

For patients with type 2 diabetes, there is an association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use ...

Dual therapy with metformin and GLP-1 RAs is associated with a lower risk for adiposity-related cancers and mortality than ...

According to a study published in Diabetes, Obesity and Metabolism, combining metformin with GLP-1 receptor agonists was ...

GLP-1 RA use with subsequent prepregnancy or early pregnancy discontinuation linked to higher risk for preterm delivery, gestational diabetes.

GLP-1 RAs probably have little or no effect on risk for thyroid cancer, pancreatic cancer, breast cancer, or kidney cancer.

GLP-1 RAs are safe and efficacious for adults with IBD, with no increased risk for flare-ups, hospitalization, corticosteroid use, or operation.

GLP-1 receptor agonists (GLP-1 RAs) are transforming metabolic disease treatment, with analytical chemists playing a critical role in formulation, stability testing, and clinical trial support for ...

A trial emulation assessed whether GLP-1RA use improves cardiovascular, kidney, and death outcomes in patients with systemic lupus erythematosus, including lupus nephritis.

BEIJING, Nov. 27, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of the ...

New advice has been issued for doctors and patients prescribed GLP-1 drugs after studies linked the medications to depression ...